University of Florida
Gainesville, Florida, 32611, United States
NCT Number: NCT01879098
The purpose of this research study is to determine whether a probiotic can change the way bile is used by the body. The investigators will also look at the effect of the probiotic on your intestinal health.
Looking for future studies?
Notify Me35 year–65 year
All sexes
Interventional
Phase 1
Gainesville, Florida, 32611, United States
This is a randomized, double-blind, placebo controlled crossover study. After obtaining informed consent, healthy, middle-aged adults with a larger waist circumference (n=30/probiotic cross with n=90 total/study) will be randomized to one of four groups: Bacillus subtilis, Lactobacillus plantarum, Bifidobacterium animalis subsp. lactis, or placebo. Participants will consume 1 capsule per day of probiotic or placebo for 6 weeks. After a 4-week washout period, participants will be crossed to the other treatment (i.e., probiotic to placebo or placebo to probiotic).
Participants will complete daily questionnaires throughout the intervention period, and one week before and after each intervention period. Blood samples will be collected at the baseline and final time points (±3 days) of each intervention. Stool samples will be collected during the pre-baseline and final weeks of each intervention. Dietary intake will be assessed weekly during each intervention period. Gastrointestinal symptoms and physical activity questionnaires will be completed weekly during each intervention period and also the weeks before and after each intervention period.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
To participate in the study you must:
Exclusion criteria
To participate in the study you must NOT:
Bacillus subtilis will be taken as a capsule once daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
Other names: Bacillus subtilis R0179
Lactobacillus plantarum will be taken as a capsule once daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
Other names: Lactobacillus plantarum HA-119
Bifidobacterium animalis will be taken as a capsule once daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
Other names: Bifidobacterium animalis subsp. lactis LAFTI B94
Placebo will be taken once daily for 6 weeks by every subject at some point in the study (crossover design).
Time frame: Baseline #1 (Week 1) to Week 8 and Baseline #2 (Week 11) to Week 18
Levels of deconjugated bile acids in the stool and in the blood will be compared between treatment periods for each subject/group.
Time frame: Baseline #1 (Week 1) to Week 8 and Baseline #2 (Week 11) to Week 18
Levels of hormones associated with hunger, satiety and glucose metabolism in the blood will be compared between treatment periods for each subject/group. Daily questionnaires will also assess hunger/satiety.
Time frame: Baseline #1 (Week 1) to Week 8 and Baseline #2 (Week 11) to Week 18
Levels of inflammatory markers in the blood will be compared between treatment periods for each subject/group.
University of Florida
Other
Evaluation of the Effect of 3 Probiotic Strains on Bile Acids, Satiety, and Inflammation in Healthy, Middle-aged Adults: a Randomized, Double-blinded, Placebo-controlled Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07008586
Behavior, Healthy
Cambridge, United Kingdom
View Trial DetailsNCT06944210
Healthy, Inflammation
Davis, California, United States
View Trial DetailsNCT06041087
Behavior, Bone
Toronto, Ontario, Canada
View Trial DetailsNCT05746845
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Orléans, France
View Trial Details